Relative Bioavailability of Two FDC Tablet Strengths of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin and Metformin Extended Release Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Empagliflozin/linagliptin/metformin (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 08 Feb 2017 Status changed from active, no longer recruiting to completed.
- 26 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.